


Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently Amended) A compound of the formula



wherein L is a radical of the formula: selected from



in which

R_1 is hydrogen, optionally substituted alkyl, aryl, heteroaryl, aralkyl or cycloalkyl;

R_2 is hydrogen, hydroxy, oxo, optionally substituted alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, alkylthio, arylthio or aralkylthio;

R_3 is hydrogen; or

R_2 and R_3 combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring; or

R_2 and R_3 combined are a bond between the carbon atoms to which they are attached;

n is zero or an integer of 1 or 2;

Y_a is hydrogen; or

Y_a and R_2 combined are a bond between the carbon atoms to which they are attached;

R_{4a} is hydrogen; or

R_{4a} and Y_a combined are a bond between the carbon atoms to which they are attached;

R and R' are independently hydrogen, halogen, optionally substituted alkyl, alkoxy, aralkyl or heteroaralkyl; or

R and R' combined together with the carbon atoms to which they are attached form an optionally substituted fused 5- to 6-membered aromatic or heteroaromatic ring

provided that R and R' are attached to carbon atoms adjacent to each other; or

$R-C$ and $R'-C$ may independently be replaced by nitrogen;


X_1 is $-Z-(CH_2)_p-Q-W$ wherein

Z is a bond, O, S, $S(O)$ or $S(O)_2$; or


Z is $-C(O)NR_5-$ in which

R_5 is hydrogen, alkyl or aralkyl;
 p is an integer from 1 to 8;
 Q is a bond; or
 Q is $-O(CH_2)_r-$ or $-S(CH_2)_r-$ in which
 r is zero or an integer from 1 to 8; or
 Q is $-O(CH_2)_{1-8}O-$, $-S(CH_2)_{1-8}O-$, $-S(CH_2)_{1-8}S-$ or $-C(O)-$; or
 Q is $-C(O)NR_6-$ in which
 R_6 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl; or
 Q is $-NR_7-$, $-NR_7C(O)-$, $-NR_7C(O)NR_8-$ or $-NR_7C(O)O-$ in which
 R_7 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;
 R_8 is hydrogen, alkyl or aralkyl;
 W is oxazole;
 X_2 is $-C(R_9)_2-$, O , S or $-NR_{10}-$ in which
 R_9 is hydrogen or lower alkyl;
 R_{10} is hydrogen, alkyl or aralkyl;
or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) The compound according to claim 1 of the formula



wherein L is a radical of the formula: selected from:



in which

R_1 is hydrogen, optionally substituted alkyl, aryl, heteroaryl, aralkyl or cycloalkyl;
 R_2 is hydrogen, hydroxy, oxo, optionally substituted alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, alkylthio, arylthio or aralkylthio;
 R_3 is hydrogen; or
 R_2 and R_3 combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring; or

R_2 and R_3 combined are a bond between the carbon atoms to which they are attached;
 n is 1;
 Y_a is hydrogen; or
 Y_a and R_2 combined are a bond between the carbon atoms to which they are attached;
 R_{4a} is hydrogen; or
 R_{4a} and Y_a combined are a bond between the carbon atoms to which they are attached;
 R and R' are independently hydrogen, halogen, optionally substituted alkyl, alkoxy,
aralkyl or heteroaralkyl; or
 R and R' combined together with the carbon atoms to which they are attached form an
optionally substituted fused 5- to 6-membered aromatic or heteroaromatic ring
provided that R and R' are attached to carbon atoms adjacent to each other; or
 Z is a bond, O or S;
 p is an integer from 1 to 8;
 Q is a bond; or
 Q is $-O(CH_2)_r$ or $-S(CH_2)_r$ in which
 r is zero or an integer from 1 to 8; or
 Q is $-C(O)NR_6-$ in which
 R_6 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or
heteroaralkyl; or
 Q is $-NR_7-$, $-NR_7C(O)-$, $-NR_7C(O)NR_8-$ or $-NR_7C(O)O-$ in which
 R_7 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or
heteroaralkyl;
 R_8 is hydrogen, alkyl or aralkyl;
 W is oxazole;
 X_2 is $-C(R_9)_2-$, O, S or $-NR_{10}-$ in which
 R_9 is hydrogen or lower alkyl;
 R_{10} is hydrogen or lower alkyl;
or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically
acceptable salt thereof.

3. (Previously Presented) The compound according to claim 2, wherein

R_1 is hydrogen or optionally substituted alkyl;
 R_2 and R_3 are hydrogen;
 Y_a is hydrogen;
 R_{4a} is hydrogen;
 R and R' are independently hydrogen, halogen, optionally substituted C_{1-6} alkyl or C_{1-6}
alkoxy;
 p is an integer from 1 to 5;

Q is a bond; or
Q is $-O(CH_2)_r$ or $-S(CH_2)_r$ in which
r is zero or 1; or
Q is $-C(O)NR_6-$ in which
R₆ is hydrogen or lower alkyl; or
Q is $-NR_7-$, $-NR_7C(O)-$, $-NR_7C(O)NR_8-$ or $-NR_7C(O)O-$ in which
R₇ is hydrogen or optionally substituted alkyl;
R₈ is hydrogen or alkyl;
X₂ is $-C(R_9)_2-$, O, S or $-NR_{10}-$ in which
R₉ is hydrogen or methyl;
R₁₀ is hydrogen;
or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.


4. (Previously Presented) The compound according to claim 3, wherein

R and R' are hydrogen;
Q is a bond; or
Q is $-O(CH_2)_r$ or $-S(CH_2)_r$ in which
r is zero; or
Q is $-NR_7-$, $-NR_7C(O)-$, $-NR_7C(O)NR_8-$ or $-NR_7C(O)O-$ in which
R₇ is hydrogen or optionally substituted lower alkyl;
or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

5. (Previously Presented) The compound according to claim 4, wherein the asymmetric center in radical L is in the (R) configuration; or a pharmaceutically acceptable salt thereof.

6. (Previously Presented) The compound according to claim 4, wherein X₂ is $-C(R_9)_2-$ in which R₉ is methyl; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers thereof.

7. (Previously Presented) The compound according to claim 4 of the formula




wherein

R_1 is hydrogen or optionally substituted alkyl;
 Z is a bond, O or S;
 p is an integer from 1 to 3;
 Q is a bond, O or S; or
 Q is $-NR_9C(O)-$ in which
 R_7 is hydrogen or optionally substituted lower alkyl;
 W is oxazole;
 X_2 is $-C(R_9)_2-$, O, S or $-NH-$ in which
 R_9 is hydrogen or methyl;
or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

8. (Cancelled)

9. (Previously Presented) The compound according to claim 7, wherein


Z is bond, O or S;
 p is an integer of 1 or 2;
 Q is a bond;
 W is selected from the group consisting of:



or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

10 (Previously Presented) The compound according to claim 9, wherein

Z is O;
 p is 1;
 X_2 is $-C(R_9)_2-$ in which R_9 is methyl;
 W is selected from the group consisting of:



or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) The compound according to claim 10, wherein the asymmetric center in radical L is in the (R) configuration; or a pharmaceutically acceptable salt thereof.

12. (Cancelled)

13. (Previously Presented) The compound according to claim 7, wherein


Z is a bond;

p is 1;

Q is $-\text{NR}_7\text{C}(\text{O})-$ in which

R₇ is hydrogen or methyl;

W is selected from the group consisting of:



or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

14 – 20. (Cancelled)

21. (Previously Presented) The compound according to claim 1 which is selected from:

(R)-1-{2-[3-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-acetyl}-pyrrolidine-2-carboxylic acid;

(R)-1-[3-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenylsulfanylcarbonyl]-pyrrolidine-2-carboxylic acid;

(R)-Pyrrolidine-1,2-dicarboxylic acid-1-[3-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl] ester;

(R)-1-{2-Methyl-2-[3-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-propionyl}-pyrrolidine-2-carboxylic acid;

(R)-1-{2-[4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-acetyl}-pyrrolidine-2-carboxylic acid;

(R)-1-{2-[4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-acetyl}-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Carbamoylphenyl)-5-methyl-oxazol-4-ylmethoxy]-phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Cyano-phenyl)-5-methyl-oxazol-4-ylmethoxy] phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Chloro-3-fluoro-phenyl)-5-methyl-oxazol-4-yl-methoxy]-phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-4-methoxy-phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Chloro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-{2-Methyl-2-[3-(5-methyl-2-p-tolyl-oxazol-4-ylmethoxy)-phenyl]-propionyl}-pyrrolidine-2-carboxylic acid;

(R)-1-(2-Methyl-2-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-phenyl}-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethyl]-phenyl}-acetyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-acetyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(2-{3-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-acetyl)-pyrrolidine-2-carboxylic acid;

(S)-1-{2-[3-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-acetyl}-pyrrolidine-2-carboxylic acid; or an optical isomer thereof; or a mixture of optical isomers thereof; or a pharmaceutically acceptable salt thereof.

22 – 24. (Cancelled)

25. (Currently Amended) The method of claim 23, wherein the condition mediated by PPAR δ is A method for the treatment of dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease, Syndrome X, and type-1 or type-2 diabetes, comprising: administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.

26. (Previously Presented) A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutically acceptable carriers.

27 – 34. (Cancelled)